DARA Biosciences Company Profile (NASDAQ:DARA)

About DARA Biosciences (NASDAQ:DARA)

DARA Biosciences logoDARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DARA
  • CUSIP: N/A
  • Web: www.darabiosciences.com/
Average Prices:
  • 50 Day Moving Avg: $0.87
  • 200 Day Moving Avg: $0.87
  • 52 Week Range: $0.67 - $1.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.93
  • P/E Growth: 0.00
  • Net Margins: -228.42%
  • Return on Equity: -145.61%
  • Return on Assets: -100.38%
  • Average Volume: 85,603 shs.

Frequently Asked Questions for DARA Biosciences (NASDAQ:DARA)

What is DARA Biosciences' stock symbol?

DARA Biosciences trades on the NASDAQ under the ticker symbol "DARA."

How were DARA Biosciences' earnings last quarter?

DARA Biosciences Inc (NASDAQ:DARA) announced its earnings results on Monday, November, 2nd. The company reported ($0.14) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.14). The business earned $1.18 million during the quarter, compared to the consensus estimate of $0.83 million. DARA Biosciences had a negative net margin of 228.42% and a negative return on equity of 145.61%. View DARA Biosciences' Earnings History.

Who are some of DARA Biosciences' key competitors?

How do I buy DARA Biosciences stock?

Shares of DARA Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DARA Biosciences' stock price today?

One share of DARA Biosciences stock can currently be purchased for approximately $0.88.

MarketBeat Community Rating for DARA Biosciences (NASDAQ DARA)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  47
MarketBeat's community ratings are surveys of what our community members think about DARA Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for DARA Biosciences (NASDAQ:DARA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for DARA Biosciences (NASDAQ:DARA)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for DARA Biosciences (NASDAQ:DARA)
Earnings by Quarter for DARA Biosciences (NASDAQ:DARA)
Earnings History by Quarter for DARA Biosciences (NASDAQ DARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2015Q3 2015($0.14)($0.14)$0.83 million$1.18 millionViewN/AView Earnings Details
8/12/2015Q215($0.15)($0.14)$0.72 million$0.99 millionViewListenView Earnings Details
5/13/2015Q115($0.12)($0.16)$0.75 million$0.65 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.11)($0.04)$0.75 million$0.72 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.13)($0.11)$0.55 million$0.60 millionViewN/AView Earnings Details
8/12/2014Q114($0.18)($0.24)$0.30 million$0.41 millionViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.37)$0.22 million$0.16 millionViewN/AView Earnings Details
11/14/2012Q312($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for DARA Biosciences (NASDAQ:DARA)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.30 EPS


Dividend History for DARA Biosciences (NASDAQ:DARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for DARA Biosciences (NASDAQ:DARA)
Insider Trades by Quarter for DARA Biosciences (NASDAQ:DARA)
Insider Trades by Quarter for DARA Biosciences (NASDAQ:DARA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/3/2013Christopher G ClementPresidentBuy14,000$0.71$9,940.00View SEC Filing  
5/30/2013Haywood D CochraneDirectorBuy10,000$0.70$7,000.00View SEC Filing  
5/23/2013Timothy James HeadyDirectorBuy10,000$0.75$7,500.00View SEC Filing  
5/17/2013David DrutzCEOBuy25,000$0.70$17,500.00View SEC Filing  
9/17/2012David DrutzCEOBuy25,000$1.06$26,500.00View SEC Filing  
9/11/2012Haywood D CochraneDirectorBuy5,000$0.80$4,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for DARA Biosciences (NASDAQ:DARA)
Latest Headlines for DARA Biosciences (NASDAQ:DARA)
wsj.com logoScientists Take New Approach to Fighting Type 1 Diabetes
www.wsj.com - June 25 at 3:02 AM
americanbankingnews.com logoRepligen (RGEN) & DARA Biosciences (DARA) Head to Head Review
www.americanbankingnews.com - June 10 at 10:10 AM
latimes.com logoWill microbes save agriculture? - Los Angeles Times
www.latimes.com - May 28 at 4:06 PM
fool.co.uk logoWill Midatech Pharma plc be the next Shire plc? - Motley Fool UK
www.fool.co.uk - May 4 at 4:08 PM
lse.co.uk logoMidatech Loss Widens On Acquisition Costs, But Revenue Surges - London South East (registration) (blog)
www.lse.co.uk - April 13 at 4:14 PM
morningstar.co.uk logoMidatech Loss Widens On Acquisition Costs, But Revenue Surges
www.morningstar.co.uk - April 13 at 4:14 PM
finance.yahoo.com logoDARA BIOSCIENCES, INC. Financials
finance.yahoo.com - December 8 at 1:16 PM
biz.yahoo.com logoMIDATECH PHARMA US INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting o
biz.yahoo.com - December 4 at 5:07 PM
biz.yahoo.com logoDARA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financi
biz.yahoo.com - December 2 at 4:32 PM
biz.yahoo.com logoDARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan
biz.yahoo.com - November 18 at 4:31 PM
biz.yahoo.com logoDARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
biz.yahoo.com - November 2 at 4:36 PM
finance.yahoo.com logoEdited Transcript of DARA earnings conference call or presentation 13-Aug-15 1:00pm GMT
finance.yahoo.com - October 19 at 1:19 PM
finance.yahoo.com logoDARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015
finance.yahoo.com - October 6 at 8:00 AM
finance.yahoo.com logoDARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush
finance.yahoo.com - October 5 at 8:00 AM
finance.yahoo.com logoDARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
finance.yahoo.com - September 23 at 4:30 PM
finance.yahoo.com logoDARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015
finance.yahoo.com - September 2 at 4:30 PM



DARA Biosciences (DARA) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff